Omalizumab Treatment in Uncontrolled Asthma and CRSwNP Patients, with Previous Endoscopic Sinus Surgery, to Improve Quality of Life and Endoscopic Outcomes: a Two-Year Real-Life Study

Real-Life Effects of Omalizumab on Chronic Rhinosinusitis with Nasal Polyposis

“…In this case, the analyzed patients showed a notable improvement in symptoms and quality of life as early as the sixteenth week. These clinical benefits persisted over 2 years [43]. The efficacy of omalizumab was also demonstrated in a real-life study conducted by Tu gba Songül Tat.…”

Efectividad real de la terapia biológica en el tratamiento de pacientes con rinosinusitis crónica con poliposis nasosinusal

“…Estos resultados en la vida real coinciden con los publicados por otros autores en numerosos estudios en los últimos dos años [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30]. Algunos trabajos han intentado comparar la efectidad real de diferebtes anticuerpos monoclonales [16][17][18].…”

“…Respecto al omalizumab, Maza et al [30] han presentado una serie retrospectiva sobre 55 pacientes con RSCcPNS y asma con una respuesta notable al biológico pasados 2 años de inicio del tratamiento. Objetivaron una mejoría temprana en los cuestionarios de calidad de vida, escalas de síntomas, NPS y SNOT 22.…”

Brazilian guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps ‒ 2024 update

“…A retrospective non-randomized real-life interventional study was conducted by Maza-Solano et al (2023), from July 2016 to November 2020, evaluating patients with CRSwNP and allergic asthma. 36 The study participants were divided into four subgroups based on surgical intervention and/or treatment administered. In Group 1 (Omalizumab + endoscopic sinus surgery), the patients had a history of previous endoscopic sinus surgery and were also treated with omalizumab; in Group 2 (Omalizumab), the patients were treated with omalizumab without a previous history of endoscopic sinus surgery; in Group 3 (endoscopic sinus surgery), the patients underwent endoscopic sinus surgery but were not treated with omalizumab; and in Group 4 (control), the patients did not undergo surgery, nor did they receive omalizumab.…”

“…The effects of both approaches may complement each other and lead to better control of the underlying inflammatory disease, with a decrease in mucous secretion, edema, and long-term polyp recurrence. 36 The often-proposed differentiation of patients with nasal polyps into non-allergic individuals with elevated blood eosinophils for choosing anti-IL-5 therapy, and allergic patients for anti-IgE treatment, is not supported by evidence. Omalizumab worked at least as well in non-allergic individuals compared to allergic individuals.…”